However, although CD8+ T effector signatures, hypoxia-related genes, and PVR-related genes have been shown to predict BLCA immunotherapy [40,41,42], these indicators often involve more genes and are difficult to measure. The gene discussed is PVR; the disease is bladder transitional cell carcinoma.